Investigators from the C.S. Mott Center for Human Growth and Development at the Wayne State University School of Medicine reported today in a publication in Cancer Immunology Research the characterisation of a novel therapeutic approach capable of restoring immune surveillance and providing long-term protection against ovarian cancer tumours.

The study, “Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumour immunological memory,” used an immune modulatory platform called CARG-2020 in collaboration with CaroGen Corp. CARG-2020, an onco-immunomodulatory vesicle, is capable of inducing in situ vaccination and activation of both arms of the immune system, leading to the development of a long-term antitumoral immune memory capable of preventing recurrence in animal models of ovarian cancer.

The team of investigators led by Gil Mor, M.D., Ph.D., scientific director of the C.S Mott Center, and Ayesha Alvero, M.D., M.S.,  director of the Ovarian Cancer Program at the C.S. Mott Center, characterised the efficacy of CARG-2020s.

“The ability of CARG-2020 to modulate the two arms of the immune system and to restore immune surveillance provides a unique protection that eliminates existing tumour, prevents tumour recurrence and provides 100% survival benefit over a long period. These findings make CARG-2020 a promising candidate for further development for human cancer immunotherapy,” Mor said.

CaroGen is finalising a protocol to advance CARG-2020 into Phase 1 clinical trials for ovarian cancer patients. This novel approach may prove more effective than existing immunotherapies, which had limited results in patients with ovarian cancer.

“More than 13,000 women die of ovarian cancer in the United States each year, and CARG-2020 could be a breakthrough immunotherapy in helping them to live longer” Alvero said. “CARG-2020 preclinical results are impressive and could potentially help to prolong and save lives in patients with ovarian cancer.”

A phase 1 clinical trial is in preparation in collaboration with investigators from the University of South Florida and CaroGen Corp.

“Our goal is to file an investigation new drug application for CARG-2020 in the second half of 2024 and conduct a safety and efficacy Phase 1/1b clinical trial in patients with ovarian cancer at University of South Florida” said Bijan Almassian, Ph.D., CaroGen’s chief executive officer.

That effort is being led by Deborah Church, M.D., chief medical officer of CaroGen, along with Dr. Mor and Thomas Rutherford, Ph.D., M.D., professor of obstetrics and division director of gynaecology oncology at the University of South Florida’s Morsani College of Medicine.

“This research at Wayne State is an excellent example of the important work that our faculty are doing in partnership with corporate partners,” said Timothy Stemmler, Ph.D., interim vice president for research. “Dr. Mor and his research team are doing critical research that are leading to great advances to improve women’s health and save lives.”

WSU received funding from CaroGen Inc. that supported part of the study.

Source: Wayne State University